DE:6BSA ETF Price & Analysis
6BSA ETF Chart & Stats
€33.01
--
Market closed
€33.01
--
Day’s Range― - ―
52-Week Range€24.86 - €34.71
Previous Close€33.01
VolumeN/A
Average Volume (3M)N/A
AUM40.88M
NAV40.81
Expense Ratio0.65%
Holdings Count130
Beta1.00
Inception DateDec 16, 2014
Next Dividend Ex-DateN/A
Dividend Yield
(1.69%)Shares OutstandingN/A
Standard DeviationN/A
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
AlphaN/A
ETF Overview
Virtus LifeSci Biotech Clinical Trials ETF
The Virtus LifeSci Biotech Clinical Trials ETF (Ticker: BBC) offers investors a dynamic opportunity to tap into the burgeoning world of biotechnology, specifically focusing on companies engaged in clinical trials. As a sector-focused exchange-traded fund, BBC zeroes in on the Health Care industry with a specialized emphasis on Life Sciences Tools & Services, a niche that plays a pivotal role in the advancement of medical research and innovation.
BBC is meticulously designed to capture the potential growth of biotech firms that are at the forefront of developing groundbreaking therapies and medical solutions. These companies are often involved in the crucial stages of clinical trials, where promising new drugs and treatments are tested for safety and efficacy. By investing in such enterprises, the ETF provides exposure to a segment of the market that is not only essential to the healthcare ecosystem but also poised for significant advancements and breakthroughs.
Investors in the Virtus LifeSci Biotech Clinical Trials ETF can expect to benefit from the rapid technological and scientific progress within the life sciences sector, making it an attractive option for those seeking to diversify their portfolios with a forward-looking, innovation-driven investment. The fund's strategic focus on clinical trials positions it uniquely within the healthcare landscape, offering both the excitement of cutting-edge scientific discovery and the potential for substantial financial returns.
Virtus LifeSci Biotech Clinical Trials ETF (6BSA) Fund Flow Chart
Virtus LifeSci Biotech Clinical Trials ETF (6BSA) 1 year Net Flows: €13M
6BSA ETF News
6BSA ETF FAQ
What was DE:6BSA’s price range in the past 12 months?
DE:6BSA lowest ETF price was €24.86 and its highest was €34.71 in the past 12 months.
What is the AUM of DE:6BSA?
As of Oct 13, 2026 The AUM of DE:6BSA is 40.88M.
Is DE:6BSA overvalued?
According to Wall Street analysts DE:6BSA’s price is currently Undervalued.
Does DE:6BSA pay dividends?
DE:6BSA does not currently pay dividends.
How many shares outstanding does DE:6BSA have?
Currently, no data Available
Which hedge fund is a major shareholder of DE:6BSA?
Currently, no hedge funds are holding shares in DE:6BSA
6BSA ETF Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
For ETFs, the calculations for the Smart Score, Analyst Consensus, Price Target, Blogger Sentiment, News Sentiment and Insider Transactions are based on the weighted average of the ETF's holdings and some additional factors. Hedge Fund Trend, Crowd Wisdom and Technicals are based on the actual ETF ticker.
Top 10 Holdings
Kodiak Sciences
2.26%
Abcellera Biologics, Inc.
1.87%
Xencor Inc.
1.58%
First Tracks Biotherapeutics Inc
1.50%
Amylyx Pharmaceuticals, Inc.
1.46%
Sellas Life Sciences Group
1.18%
Vaxcyte, Inc.
1.15%
4D Molecular Therapeutics, Inc.
1.14%
Replimune Group
1.14%
MBX Biosciences, Inc.
1.14%
Total14.42%
See All Holdings






